https://www.selleckchem.com/pr....oducts/bms309403.htm
DWP14012 (fexuprazan), a novel potassium-competitive acid blocker, is under development for the treatment of acid-related disorders. To compare the pharmacodynamics (PDs), pharmacokinetics (PKs) and safety of DWP14012 among healthy subjects of Korean, Caucasian and Japanese descent. A randomised, double-blind, placebo-controlled, single- and multiple-dose study was conducted. Ten subjects in each dose group (40, 60 or 80mg for Koreans; 40 or 80mg for Caucasians; 20, 40 or 80mg for Japanese) were randomly assigned to DWP14012 or a plac
Like
Comment
Share
